Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...
Since then, Musk hasn’t hidden his anger with Altman and OpenAI. He’s currently suing the company over its decision to become ...
Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...
The dispute between arguably the two biggest names in generative artificial intelligence—billionaires Sam Altman and Elon Musk—erupted this week after President Donald Trump announced a $500 ...
OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act autonomously on the web. But OpenAI is not Altman's ...
Trump was joined by Oracle founder Larry Ellison, OpenAI CEO Sam Altman, and SoftBank CEO Masayoshi Son, who said the ...
The race to increase human life span through ... that’s set to enter an early-stage trial in Australia this year. Some of the investment will come from OpenAI CEO Sam Altman, who also provided ...